De definitieve gids voor genbewerking.
Menu
Home Leren Nieuws Vraag de Atlas
Verkennen Technologieën Ziekten Behandelingen Klinische onderzoeken Bedrijven Wetenschappers Genen Onderzoek Instellingen
Verder dan geneeskunde Landbouw Ethiek Investeren Wereldkaart
Leren & Tools Begin hier Woordenlijst A–Z Vergelijk technologieën Tijdlijn Lijsten & Rankings AI-agents ★ Opgeslagen API
Over Over ons Methodologie Databronnen Redactioneel beleid Contact Disclaimers

🧭 Begeleide weergave
Nieuw in de genetica? We leggen elk begrip uit terwijl je bladert, in gewone taal. Dezelfde pagina's, met de hulp ingebouwd.

⚡ Expertvisie
Je kent de biologie al. Alleen de inhoud — helder en compact, zonder extra uitleg. Dit is de standaardweergave.

Interfacetaal
Lichte modus

Disease · Infectious disease

HIV

A virus that hides inside the genome of the cells it infects — which is why editing has been proposed both to block entry and to cut the virus out.

Phase I CCR5virusexcision
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Eenvoudige uitleg

HIV infects immune cells and then writes its own genes into their DNA, where drugs cannot reach it. Daily medication keeps the virus suppressed, but stop the medication and the hidden copies wake up. Two editing ideas follow from that. The first removes the doorway the virus uses to get into cells — a gene called CCR5, which some people are naturally born without and who are largely resistant to infection. The second tries to cut the viral DNA out of the genome directly.

Dieper ingaan

HIV integrates as a provirus into host cell DNA, establishing a latent reservoir that antiretroviral therapy suppresses but does not eliminate. Editing strategies target CCR5, the principal co-receptor for R5-tropic HIV — homozygous CCR5-Δ32 individuals are largely resistant, and allogeneic transplant from CCR5-Δ32 donors has produced sustained remission in a small number of patients — or attempt excision of integrated provirus. Sangamo's zinc-finger CCR5 disruption programme was the first human gene-editing trial of any kind.

Why the natural experiment matters

About one per cent of people of northern European ancestry carry two copies of CCR5-Δ32, a deletion that removes the receptor, and they are largely resistant to the common form of HIV while appearing otherwise healthy. A small number of patients — beginning with Timothy Ray Brown, the 'Berlin patient' — have achieved long-term remission after receiving bone marrow transplants from CCR5-Δ32 donors for unrelated cancers. That is proof the biology works. The problem is that a marrow transplant is a dangerous procedure that no one would undergo for HIV alone, given how well antiretroviral therapy works.

Honest status

Editing approaches to HIV remain early-phase and have not produced durable control off medication in trials. The comparator is genuinely excellent: modern antiretroviral therapy gives near-normal life expectancy. Any editing approach has to beat that on convenience or on cure, and neither has been shown.

ImportantThis is also the area of the field's worst episode: in 2018 He Jiankui edited CCR5 in human embryos and brought about the birth of edited children, an act condemned worldwide and for which he was imprisoned. That was germline editing of healthy embryos, and it is unrelated to the legitimate somatic research described here.
Honest status
Virus particles at the surface of an immune cell, at the receptor they use to enter. Illustration generated for The CRISPR Atlas — a visual aid, not a photograph or a literal depiction of molecular structure.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Alleen educatieve informatie Deze pagina is een naslagbron, geen medisch advies. Onderzoeks- en regelgevingsstatus veranderen; controleer de datum van de laatste update hierboven en verifieer belangrijke informatie bij de vermelde primaire bronnen.